← Leaderboards
William A. Wegener
Immunomedics, Inc.
$2,714,853
Attributed
$2,714,853
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2009–13$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,714,853 · 4
By mechanism
R44$1,997,013 · 1
R43$717,840 · 3
Top collaborators
No co-investigators on record.
Most similar at Immunomedics, Inc.
Same institution · by research overlap
- Serengulam V Govindan$2,256,181
- Chien Hsing K. Chang$1,347,339
- Donglin Liu$200,782
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsImmunoglobulin GDoseTumorPreclinical StudyAntibodiesLabelS LymphomaClinical TrialsMonitorSmall Business Innovation Research GrantPre-ClinicalResponseSafetyDrug KineticsBaseAntigensImageDesignRadioimmunotherapyClinical ResearchRadionuclide ImagingMaximum Tolerated DoseMonkeys
Grant awards (5)
Combined radio- and immunotherapy of aggressive NHL$1,137,221
R44 · FY2013 · CA · contact PI
Localization of Pancreatic Cancer by a Pretargeted 18F-Hapten-Peptide$213,982
R43 · FY2013 · CA · contact PI
Bispecific antibody pretargeted immunoPET of prostate cancer$276,833
R43 · FY2012 · CA · contact PI
Humanized Anti-Trop2-SN-38 Conjugate For Advanced Pancreatic Cancer$227,025
R43 · FY2012 · CA · contact PI
Combined radio- and immunotherapy of aggressive NHL$859,792
R44 · FY2009 · CA · contact PI